Monday, December 29, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc.

Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer ...

Investors who use a better approach can find quality stocks trading at discounts of 40% or more to the market. Some ETFs and ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Radiation therapy combined with Keytruda increased T cell infiltration in HR+ and HER2-negative breast cancer, enhancing immune response. High-dose radiation with Keytruda led to increased ...

A court in Munich has granted a preliminary injunction that will prevent MSD from distributing the subcutaneous version of its cancer immunotherapy Keytruda in the German market. The verdict is the ...

Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the best emerging technology stocks to invest in. On December 16, Inhibrx ...

Key stocks like Adani Green, Titan, and Biocon are poised for growth due to strategic expansions and strong project ...

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Merck stock reached a new 52-week high, hitting $106.08, reflecting a steady upward trend in the pharmaceutical giant’s market performance. According to InvestingPro data, the stock is trading at an ...